Additionally, when PB or BM blast ranges from 10–19%, patients with not only multi-hit, but also single TP53 mutation would be classified as MDS/AML with mutated TP53. Thus, 14 patients (23.3%) in the MDS or MDS/AML group with mutated TP53 in the ICC were classified as MDS-IB or MDS-f in WHO-2022 classfication (Table 1, Fig. 1). The gene discussed is TP53; the disease is acute myeloid leukemia.